ORTHOCELL LIMITED — Capital/Financing Update 2025

Nov 13, 2025

==> picture [596 x 97] intentionally omitted <==

Notice under Section 708A(5)(e) of the Corporations Act

14 November 2025: Orthocell Limited ASX: OCC, “Orthocell” or “the Company”) is pleased to advise that it has today issued the remaining 230,770 fully paid ordinary shares ( Shares ) at an issue price of $1.30 per Share in accordance with the terms of a capital raising announced to the ASX on 17 October 2025.

The Company gives notice under section 708(5)(e) of the Corporations Act 2001 (Cth) (“ Act ”) that:

• (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;

• (b) the notice is being given under section 708A(5)(e) of the Act;

• (c) as at the date of this notice the Company has complied with:

• (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and

• (ii) sections 674 and 674A of the Act; and

• (d) as at the date of this notice, there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act that is required to be set out in this notice,

Release authorised by the Board of Orthocell Limited.

For more information, please contact:

General enquiries Media enquiries Investor enquiries Paul Anderson Haley Chartres Shaun Duffy Orthocell Limited H^CK Director VECTOR Advisors CEO and MD P: +61 8 9360 2888 P: +61 423 139 163 P: +61 404 094 384 E: paul.anderson@orthocell.com E: haley@hck.digital E: sduffy@vectoradvisors.au

==> picture [596 x 76] intentionally omitted <==

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors and recorded initial sales. The Company’s flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand and Canada. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,” “project,” “target, ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

==> picture [596 x 76] intentionally omitted <==